MedTrace Logo

Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2

NCT05482074 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2024-01-19

No results posted yet for this study

Summary

The purpose of this study is to evaluate how effective Olaparib is when given as a treatment for primary or recurrent, unresectable or metastatic melanoma. This research study involves targeted therapy.

-The name of the study drug involved in this study is: Olaparib (also known as Lynparza)

Conditions

Interventions

DRUG

Olaparib

Oral, twice a day, dosage per protocol, per 28 day cycle

Sponsors & Collaborators

Principal Investigators

  • Tamara Sussman, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-04
Primary Completion
2026-05-01
Completion
2027-05-01
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05482074 on ClinicalTrials.gov